| Isabell Fetsch, OTD | |
|
8890 E Legacy Blvd, Scottsdale, AZ 85255-2024 | |
| (480) 680-7126 | |
| Not Available |
| Full Name | Isabell Fetsch |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 8890 E Legacy Blvd, Scottsdale, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720866924 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Provider Name | Empowerme Rehabilitation Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1144954074 PECOS PAC ID: 2769723162 Enrollment ID: O20230127000420 |
News Archive
According to a survey by Pew Research, nearly two-thirds of adults in the U.S. collect their own data on at least one health indicator through the use of tracking devices and apps, and it is estimated by industry analysts that over 30 million Americans have access to their sleep data.
Administration officials sent letters to college and university presidents and student body leaders reminding them to communicate to students about how, because of changes resulting from the health overhaul, they can remain on a parent's plan until age 26. In other health reform news, President Obama says that he is flexible on health reform, and the AP reports on how the absence of one Supreme Court justice on certain legal questions has been "no big deal."
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.
A brain circuit that works as a "brake" on binge alcohol drinking may help explain male-female differences invulnerability to alcohol use disorders, according to a preclinical study led by scientists at Weill Cornell Medicine.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Isabell Fetsch, OTD 6900 E Princess Dr Unit 1133, Phoenix, AZ 85054-4104 Ph: () - | Isabell Fetsch, OTD 8890 E Legacy Blvd, Scottsdale, AZ 85255-2024 Ph: (480) 680-7126 |
News Archive
According to a survey by Pew Research, nearly two-thirds of adults in the U.S. collect their own data on at least one health indicator through the use of tracking devices and apps, and it is estimated by industry analysts that over 30 million Americans have access to their sleep data.
Administration officials sent letters to college and university presidents and student body leaders reminding them to communicate to students about how, because of changes resulting from the health overhaul, they can remain on a parent's plan until age 26. In other health reform news, President Obama says that he is flexible on health reform, and the AP reports on how the absence of one Supreme Court justice on certain legal questions has been "no big deal."
Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.
Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.
A brain circuit that works as a "brake" on binge alcohol drinking may help explain male-female differences invulnerability to alcohol use disorders, according to a preclinical study led by scientists at Weill Cornell Medicine.
› Verified 4 days ago
Ms. Attria Batoon Honda, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 12000 N 90th T., Scottsdale, AZ 85260 Phone: 480-451-2033 | |
Jennifer Klaine, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1475 N Granite Reef Rd, Scottsdale, AZ 85257 Phone: 480-990-1904 | |
Jared Stuck, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 16413 N 91st St Bldg C145, Scottsdale, AZ 85260 Phone: 480-447-3262 Fax: 480-630-2066 | |
Emily Ludwig, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 13802 N Scottsdale Rd Ste 163, Scottsdale, AZ 85254 Phone: 480-401-1848 | |
Siyu Yi, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 7025 N Scottsdale Rd Ste 200, Scottsdale, AZ 85253 Phone: 602-385-8733 | |
Ms. Connie Sue Williams, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8115 E Indian Bend Rd, Ste 123, Scottsdale, AZ 85250 Phone: 480-951-6451 | |
Tonya Lee Soules, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8429 E Via De Jardin, Scottsdale, AZ 85258 Phone: 480-664-1266 |